Samjin Pharmaceuticals Future Growth
Future criteria checks 0/6
Samjin Pharmaceuticals is forecast to grow revenue at 6.4% per annum.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Pharmaceuticals earnings growth | 35.3% |
| Revenue growth rate | 6.4% |
| Future return on equity | 7.5% |
| Analyst coverage | Low |
| Last updated | 20 Aug 2024 |
Recent future growth updates
No updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 356,100 | N/A | 13,900 | 32,100 | 1 |
| 12/31/2025 | 329,000 | N/A | 17,400 | 33,800 | 1 |
| 12/31/2024 | 307,000 | N/A | 12,900 | 16,900 | 1 |
| 12/31/2022 | 274,032 | 21,894 | -18,205 | 17,293 | N/A |
| 12/31/2021 | 250,070 | 28,404 | -50,258 | 23,967 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if A005500's forecast earnings growth is above the savings rate (2.7%).
Earnings vs Market: Insufficient data to determine if A005500's earnings are forecast to grow faster than the KR market
High Growth Earnings: Insufficient data to determine if A005500's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: A005500's revenue (6.4% per year) is forecast to grow slower than the KR market (8.9% per year).
High Growth Revenue: A005500's revenue (6.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: A005500's Return on Equity is forecast to be low in 3 years time (7.5%).
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 19:26 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2022/12/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Samjin Pharmaceuticals Co., Ltd. is covered by 10 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hyung Soo Kim | Cape Investment & Securities Co., Ltd. |
| Hyuk Jin Yoon | Eugene Investment & Securities Co Ltd. |
| Jae Hoon Shin | Hanwha Investment & Securities Co., Ltd. |